Stock Fundamentals

Reality Check: Biosimilar cheer for Biocon

Dhuraivel Gunasekaran | Updated on March 10, 2018 Published on December 10, 2017


The stock of Biocon surged as much as 16 per cent last Monday. This was after US drug regulator FDA approved Mylan’s Ogivri — a biosimilar version of Roche’s breast-cancer drug Herceptin.

Mylan and Biocon are partners for biosimilar products. Mylan will market Ogivri in the US, Europe and other key markets while Biocon will manufacture and supply the product on a cost-plus-profit sharing basis. The innovator drug Herceptin has annual sales of $2.6 billion in the US and global sales of $6.9 billion.

Mylan and Biocon are the only players to have settled with Roche for launch of the biosimilar in the US and Europe. The approval has increased hope for further approvals from the Biocon-Mylan biosimilar pipeline. Awaiting approval is the Neulasta biosimilar (oncology) that has annual sales of $3.9 billion in the US.

Biocon is the first Indian pharmaceutical company to receive approval for biosimilar in the US, attesting to its capabilities in the space.

Read further by subscribing to

The Hindu Businessline

What You'll Get

  • Web + Mobile

    Access exclusive content of the Hindu Businessline across desktops, tablet and mobile device.


  • Exclusive portfolio stories and investment advice

    Gain exclusive market insights from the Hindu Businessline's research desk.


  • Ad free experience

    Experience cleaner site with zero ads and faster load times.


  • Personalised dashboard

    Customize your preference and get a personalized recommendation of stories based on your intrest.

This article is closed for comments.
Please Email the Editor